Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Hanafi, Laïla Aïcha ^a   Gauchat, Dominique ^a   Godin Ethier, Jessica ^a   Possamaï, David ^a   Duvignaud, Jean Baptiste ^b,c   Leclerc, Denis ^b   Grandvaux, Nathalie ^d   Lapointe, Réjean ^a  

^a Institut du Cancer de Montreal   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; STAT1 PROTEIN; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; PROTEASOME; SMALL INTERFERING RNA; VIDARABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; MELANOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; PROTEIN STABILITY; RNA INTERFERENCE; TUMOR CELL CULTURE;

ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; DOWN-REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 84902589930     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099211     Document Type: Article

References (44)

1. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, et al. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193. (Pubitemid 28406294)
2. Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ (2011) Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 18: 2257-2262.
3. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R (2011) Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 17: 6985-6991.
4. Godin-Ethier J, Pelletier S, Hanafi LA, Gannon PO, Forget MA, et al. (2009) Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J Immunol 183: 7752-7760.
5. Sharma MD, Hou DY, Baban B, Koni PA, He Y, et al. (2010) Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 33: 942-954.
6. Cady SG, Sono M (1991) 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL- alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL- alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 291: 326-333.
7. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, et al. (2011) The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One 6: e19823.
8. Munn DH (2012) Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed) 4: 734-745.
9. Heitger A (2011) Regulation of expression and function of IDO in human dendritic cells. Curr Med Chem 18: 2222-2233.
10. Taylor MW, Feng GS (1991) Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5: 2516-2522. (Pubitemid 21905800)
11. Jeong YI, Kim SW, Jung ID, Lee JS, Chang JH, et al. (2009) Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. J Biol Chem 284: 3700-3708.
12. Cheng CW, Shieh PC, Lin YC, Chen YJ, Lin YH, et al. (2010) Indoleamine 2,3- dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocate-chin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. J Agric Food Chem 58: 887-894.
13. Noh KT, Chae SH, Chun SH, Jung ID, Kang HK, et al. (2013) Resveratrol suppresses tumor progression via the regulation of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 431: 348-353.
14. Lee HJ, Jeong YI, Lee TH, Jung ID, Lee JS, et al. (2007) Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells. Biochem Pharmacol 73: 1412-1421. (Pubitemid 46463948)
15. Lu K, Wang X (2012) Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol 5: 55.
16. Frank DA, Mahajan S, Ritz J (1999) Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 5: 444-447. (Pubitemid 29180586)
17. Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD (2008) STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood 111: 2062-2072. (Pubitemid 351451518)
18. Hui Z, Tretiakova M, Zhang Z, Li Y, Wang X, et al. (2009) Radiosensitization by inhibiting STAT1 in renal cell carcinoma. Int J Radiat Oncol Biol Phys 73: 288-295.
19. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, et al. (1995) Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 55: 3149-3157.
20. Godin-Ethier J, Hanafi LA, Duvignaud JB, Leclerc D, Lapointe R (2011) IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive. Mol Immunol 49: 253-259.
21. Torella D, Curcio A, Gasparri C, Galuppo V, De Serio D, et al. (2007) Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. Am J Physiol Heart Circ Physiol 292: H2935-2943. (Pubitemid 47084544)
22. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, et al. (2006) Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 580: 755-762.
23. Yuan B, Zhang J, Wang H, Xiong L, Cai Q, et al. (2011) 6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1. Cancer Res 71: 1904-1911.
24. Hernandez-Breijo B, Monserrat J, Ramirez-Rubio S, Cuevas EP, Vara D, et al. (2011) Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma. World J Gastroenterol 17: 3899-3911.
25. Rachakatla RS, Pyle MM, Ayuzawa R, Edwards SM, Marini FC, et al. (2008) Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. Cancer Invest 26: 662-670.
26. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, et al. (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8: 333-338. (Pubitemid 28072702)
27. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J (1999) The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5: 2638-2645. (Pubitemid 29437352)
28. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, et al. (2008) SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A 105: 20828-20833.
29. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, et al. (2005) Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 175: 5601-5605. (Pubitemid 41508038)
30. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, et al. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343: 1750-1757.
31. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854. (Pubitemid 35231542)
32. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, et al. (2002) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25: 243-251. (Pubitemid 34533314)
33. Mailankot M, Nagaraj RH (2010) Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human lens epithelial cells: apoptosis through the formation of 3-hydroxykynurenine. Int J Biochem Cell Biol 42: 1446-1454.
34. Gamberale R, Fernandez-Calotti P, Sanchez-Avalos J, Alberto MF, Geffner J, et al. (2006) The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia. Haematologica 91: 574-576.
35. Pallotta MT, Orabona C, Volpi C, Grohmann U, Puccetti P, et al. (2010) Proteasomal Degradation of Indoleamine 2,3-Dioxygenase in CD8 Dendritic Cells is Mediated by Suppressor of Cytokine Signaling 3 (SOCS3). Int J Tryptophan Res 3: 91-97.
36. Jiang GM, He YW, Fang R, Zhang G, Zeng J, et al. (2010) Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and posttranscriptional levels. Int J Biochem Cell Biol 42: 1840-1846.
37. Novitskiy SV, Moses HL (2012) Turn off the IDO: will clinical trials be successful? Cancer Discov 2: 673-675.
38. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, et al. (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17: 1094-1100.
39. Fallarino F, Grohmann U, Puccetti P (2012) Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur J Immunol 42: 1932-1937.
40. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, et al. (2011) Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 12: 870-878.
41. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357. (Pubitemid 46218728)
42. de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, et al. (2009) Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant 44: 81-87.
43. Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24: 207-212.
44. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133.